E-ISSN: 1308-5263
Turk J Hematol. 2025; 42(1): 65-68 | DOI: 10.4274/tjh.galenos.2025.2024.0386
2Federal University of Ceara, Center for Research and Drug Development (NPDM), Cancer Cytogenomic Laboratory, Fortaleza, Brazil
3Federal University of Ceara, Post-Graduate Program of Pathology, Fortaleza, Brazil; Federal University of Ceara, Center for Research and Drug Development (NPDM), Cancer Cytogenomic Laboratory, Fortaleza, Brazil
4Federal University of Ceara, Post-Graduate Program of Pathology, Fortaleza, Brazil; Federal University of Ceara, Center for Research and Drug Development (NPDM), Cancer Cytogenomic Laboratory, Fortaleza, Brazil; Federal University of Ceara, Post-Graduate Program of Translational Medicine, Fortaleza, Brazil
Keywords: IRF4, Myelodysplastic neoplasm, Polymorphism, Risk
2Federal University of Ceara, Center for Research and Drug Development (NPDM), Cancer Cytogenomic Laboratory, Fortaleza, Brazil
3Federal University of Ceara, Post-Graduate Program of Pathology, Fortaleza, Brazil; Federal University of Ceara, Center for Research and Drug Development (NPDM), Cancer Cytogenomic Laboratory, Fortaleza, Brazil
4Federal University of Ceara, Post-Graduate Program of Pathology, Fortaleza, Brazil; Federal University of Ceara, Center for Research and Drug Development (NPDM), Cancer Cytogenomic Laboratory, Fortaleza, Brazil; Federal University of Ceara, Post-Graduate Program of Translational Medicine, Fortaleza, Brazil
Anahtar Kelimeler: IRF4, Myelodisplastik neoplasmlar, Polimorfizm, Risk Ethics
IRF4 rs12203592 Risk Variant Shows Effect in European But Not Non-European and Admixed Myelodysplastic Syndrome Patients
Jonas Nogueira Ferreira Maciel Gusmão1, Alessandro Cavalcante Chaves2, João Vitor Caetano Goes3, Ronald Feitosa Pinheiro2, Ronald Feitosa Pinheiro41Federal University of Ceara, Post-Graduate Program of Pathology, Fortaleza, Brazil2Federal University of Ceara, Center for Research and Drug Development (NPDM), Cancer Cytogenomic Laboratory, Fortaleza, Brazil
3Federal University of Ceara, Post-Graduate Program of Pathology, Fortaleza, Brazil; Federal University of Ceara, Center for Research and Drug Development (NPDM), Cancer Cytogenomic Laboratory, Fortaleza, Brazil
4Federal University of Ceara, Post-Graduate Program of Pathology, Fortaleza, Brazil; Federal University of Ceara, Center for Research and Drug Development (NPDM), Cancer Cytogenomic Laboratory, Fortaleza, Brazil; Federal University of Ceara, Post-Graduate Program of Translational Medicine, Fortaleza, Brazil
Keywords: IRF4, Myelodysplastic neoplasm, Polymorphism, Risk
IRF4 rs12203592 Risk Varyantı, Avrupalı Miyelodisplastik Sendrom Hastalarında Etkili Ancak Avrupalı Olmayan ve Karışık Kökenli Hastalarda Etkili Değil
Jonas Nogueira Ferreira Maciel Gusmão1, Alessandro Cavalcante Chaves2, João Vitor Caetano Goes3, Ronald Feitosa Pinheiro2, Ronald Feitosa Pinheiro41Federal University of Ceara, Post-Graduate Program of Pathology, Fortaleza, Brazil2Federal University of Ceara, Center for Research and Drug Development (NPDM), Cancer Cytogenomic Laboratory, Fortaleza, Brazil
3Federal University of Ceara, Post-Graduate Program of Pathology, Fortaleza, Brazil; Federal University of Ceara, Center for Research and Drug Development (NPDM), Cancer Cytogenomic Laboratory, Fortaleza, Brazil
4Federal University of Ceara, Post-Graduate Program of Pathology, Fortaleza, Brazil; Federal University of Ceara, Center for Research and Drug Development (NPDM), Cancer Cytogenomic Laboratory, Fortaleza, Brazil; Federal University of Ceara, Post-Graduate Program of Translational Medicine, Fortaleza, Brazil
Anahtar Kelimeler: IRF4, Myelodisplastik neoplasmlar, Polimorfizm, Risk Ethics
Corresponding Author: Jonas Nogueira Ferreira Maciel Gusmão, Brazil
Manuscript Language: English
Manuscript Language: English
Copyright © 2025 Turkish Journal of Hematology